We report the development of a dual-modal(PET/NIRF) immunoconjugate ([89Zr]Zr-DFO-anti-MT1-MMP-IRDye800CW)that targets MT1-MMP, a matrix metalloproteinase overexpressed inhigh-grade sarcomas. The gene discussed is MMP14; the disease is sarcoma.